Robert J Lee PhD

Robert J Lee PhD
ProfessorCollege of Pharmacy
542 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:Fax: 614-292-7766
  • Leukemia Research

General Research Interest

Targeted drug delivery systems. Liposomes and nanoparticles. Delivery systems for genes, antisense oligos, siRNA and miRNA.  Targeted imaging and therapeutic agents for tumors.  Novel bioconjugates.

Research Description

Robert J. Lee, Ph.D., Professor of Pharmaceutics, is a member of the OSU Comprehensive Cancer Center, the OSU Nanotechnology Center NSF-NSEC and a faculty at OSU College of Pharmacy since 1997 (tenured since 2002). He is an expert on targeted nanoparticle and liposomal drug delivery systems. He obtained his Ph.D. in Biochemistry at Purdue University, worked as a Senior Scientist at GeneMedicine Inc. in 1995-1996 and was involved in R&D of gene therapy based on lipid nanoparticles.  He then served as Vice President of R&D at Endocyte, Inc., where he was involved in the successful effort in taking 111In-DTPA-folate into a Phase I/II clinical trial. At OSU, Dr. Lee has published ~ 80 original research articles, reviews, and book chapters and was inventor on several patents in the area of nanomedicine.  He was the PI or co-PI on several NIH R01, R21, R43, R44 grants and grants from Leukemia Lymphoma Society, American Cancer Society, and DOD’s Congressional Directed Medical Research Program (CDMRP) in breast cancer.  He regularly serves on NCI grant review panels.

Transinstitutional Work

Dr. Lee had a close collaboration with Dr. Manohar Ratnam at the University of Toledo Medical School for a number of years. He is involved in the OSU NSEC, which is a multi-institutional center. Dr. Lee has very close collaborations with several colleagues in other colleges, including College of Medicine and Public Health, Biological Sciences and Veterinary Biosciences.

Current Publications

  • Yang Z, Yu B, Zhu J, Huang X, Xie J, Xu S, Yang X, Wang X, Yung BC, Lee LJ, Lee RJ, Teng LA microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.Nanoscale 6 9742-9751 8/21/2014
  • Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy NTumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.Leukemia in press 6/20/2014
  • Yu B, Wang X, Zhou C, Teng L, Ren W, Yang Z, Shih CH, Wang T, Lee RJ, Tang S, Lee LJInsight into Mechanisms of Cellular Uptake of Lipid Nanoparticles and Intracellular Release of Small RNAs.Pharm Res in press 4/17/2014
  • Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy NA novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Nanomedicine 10 393-400 2/1/2014
  • Wang X, Yu B, Ren W, Mo X, Zhou C, He H, Jia H, Wang L, Jacob ST, Lee RJ, Ghoshal K, Lee LJEnhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.J Control Release 172 690-8 12/28/2013
  • Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, Huang K, Castro CE, Paulaitis M, Nana-Sinkam SP, Lee LJDetection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.Anal Chem 85 11265-74 12/3/2013
  • Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Muñoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, Brook DL, Garman S, Dorrance AM, Zhang X, Zhang J, Lee RJ, Blum W, Caligiuri MA, Marcucci GEradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Blood 122 3778-83 11/28/2013
  • Hsu SH, Yu B, Wang X, Lu Y, Schmidt CR, Lee RJ, Lee LJ, Jacob ST, Ghoshal KCationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.Nanomedicine 9 1169-80 11/1/2013
  • Paecharoenchai O, Teng L, Yung BC, Teng L, Opanasopit P, Lee RJNonionic surfactant vesicles for delivery of RNAi therapeutics.Nanomedicine (Lond) 8 1865-73 11/1/2013
  • Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ, Muthusamy NTargeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Biomaterials 34 6185-93 8/1/2013
  • Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K, Lee RJLactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.J Control Release 168 251-61 6/28/2013
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci GTargeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Clin Cancer Res 19 2355-67 5/1/2013
  • Zhou C, Zhang Y, Yu B, Phelps MA, Lee LJ, Lee RJComparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.Nanomedicine 9 504-13 5/1/2013
  • Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy NMilatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Clin Cancer Res 19 347-56 1/15/2013
  • Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy NTargeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.Blood 121 136-47 1/3/2013
  • Povoski SP, Chapman GJ, Murrey DA, Lee R, Martin EW, Hall NCIntraoperative detection of ¹⁸F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria.BMC Cancer 13 98 1/1/2013
  • Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, Lee LJ, Nana-Sinkam SPTherapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.Mol Ther Nucleic Acids 2 e84 1/1/2013
  • Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJHuman serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.Nanomedicine 9 122-9 1/1/2013
  • Teng L, Jiang C, Sun F, Li C, Teng L, Meng Q, Lee RJ, Li YLong-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder.J Microencapsul 30 116-23 1/1/2013
  • Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, Wu YZ, Heerema NA, Chan KK, Perrotti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri MAAberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.Cancer Cell 22 645-55 11/13/2012
  • Yu B, Hsu SH, Zhou C, Wang X, Terp MC, Wu Y, Teng L, Mao Y, Wang F, Xue W, Jacob ST, Ghoshal K, Lee RJ, Lee LJLipid nanoparticles for hepatic delivery of small interfering RNA.Biomaterials 33 5924-34 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu